张青, 郝晓柯, 苏明权, 刘家云, 张鹏. 抗前列腺癌γ-精浆蛋白人源Fab抗体的原核表达和特性鉴定[J]. 中国肿瘤临床, 2011, 38(15): 902-905. DOI: 10.3969/j.issn.1000-8179.2011.15.009
引用本文: 张青, 郝晓柯, 苏明权, 刘家云, 张鹏. 抗前列腺癌γ-精浆蛋白人源Fab抗体的原核表达和特性鉴定[J]. 中国肿瘤临床, 2011, 38(15): 902-905. DOI: 10.3969/j.issn.1000-8179.2011.15.009
Qing ZHANG, Xiaoke HAO, Mingquan SU, Jiayun LIU, Peng ZHANG. Prokaryotic Expression and Biological Analysis of Humanized Anti-gamma-Semino-protein Fab Antibody against Prostate Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 38(15): 902-905. DOI: 10.3969/j.issn.1000-8179.2011.15.009
Citation: Qing ZHANG, Xiaoke HAO, Mingquan SU, Jiayun LIU, Peng ZHANG. Prokaryotic Expression and Biological Analysis of Humanized Anti-gamma-Semino-protein Fab Antibody against Prostate Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 38(15): 902-905. DOI: 10.3969/j.issn.1000-8179.2011.15.009

抗前列腺癌γ-精浆蛋白人源Fab抗体的原核表达和特性鉴定

Prokaryotic Expression and Biological Analysis of Humanized Anti-gamma-Semino-protein Fab Antibody against Prostate Cancer

  • 摘要: 对从噬菌体抗体库筛选的抗γ-精浆蛋白(γ-sm)人源化Fab抗体进行表达纯化和生物学特性鉴定,为其应用于前列腺癌抗体导向酶-前药治疗奠定基础。方法:首先将重组表达载体γ-sm-hFab/pComb3X转化大肠杆菌并诱导其可溶性表达,亲和纯化后采取Western-blot检测表达产物对γ-sm抗原结合特异性。其次分别采用抑制ELISA和竞争抑制ELISA方法分析表达纯化的抗γ-sm人源Fab抗体的亲和力和结合表位。最后采用竞争抑制流式细胞术和免疫组化超敏S-P法鉴定制备纯化的人源Fab抗体在前列腺癌细胞和组织上的结合分布特性。结果:成功诱导表达和纯化出理论分子量大小可溶性Fab抗体蛋白,含量约占细菌总可溶性蛋白的20.5%,Western-blot证实其能特异性结合识别γ-sm。抑制ELISA显示其表观结合常数(Ka)为0.78×108 M-1,亲和力约为亲本鼠源单抗E4B7的37.5%,竞争抑制ELISA进一步显示,二者识别γ-Sm抗原蛋白上的表位相同。流式细胞术和免疫组化显示,表达纯化的人源Fab抗体可显著地与前列腺癌细胞和组织特异性结合,其结合主要分布在腺上皮内瘤和中低度恶性的前列腺癌组织上。结论:成功地对筛选的抗γ-sm人源Fab抗体进行了原核可溶性表达、纯化和免疫生物学特性鉴定,为其进一步应用于抗体导向酶-前药实验治疗前列腺癌奠定了基础。

     

    Abstract: To express, purify, and identify humanized anti-gamma-seminoprotein (γ-sm) Fab antibody screened from phage antibody library and to use it for antibody directed enzyme prodrug therapy for prostate cancer in the future. Methods: Recombinant phagemid DNA ( γ-sm-hFab/pComb3X ) was transformed into E. coli for soluble expression with IPTG induction followed by purification with immunoaffinity chromatography. The relative affinity and binding epitope of purified γ-sm-hFab were determined by inhibitory ELISA and competitive inhibitory ELISA respectively. The cellular and tissue binding specificity of purified γ-sm-hFab were validated by competitive flow cytometry and immunohistochemistry staining respectively, based on tissue microarray. Results: SDS-PAGE showed that the gene of humanized anti-γ-sm Fab antibody was successfully expressed in soluble form and was well purified. Smartview scanning indicated that the quantity of the expression product accounted for 20.5% of the concentrated bacterial total soluble protein. Western blot analysis was used to confirm further the purified product of this Fab antibody specifically bound to γ-sm, regardless of whether it was deglycosylated or not. ELISA inhibition curves demonstrated that the parent binding constant (Ka) is 0.78×108 M-1, which is about 37.5% of the relative affinity in the parent E4B7 mAb. Competitively inhibitory ELISA indicated that the humanized Fab antibody and parental E4B7 mAb can recognize the same antigen epitope. Flow cytometry showed significant binding of the humanized Fab antibody to LnCap and PC3M cell surface. This specific binding was further confirmed by immunocytochemical staining with the strongest immunoreactivity both on HGPIN and on Gleason 3 prostatic adenocarcinoma tissues. Conclusion: Succcessful prokaryotic expression, purification, and immunobiological binding analysis of the selected humanized anti-γ-sm Fab antibody lay the foundation for the optimal antibody-directed enzyme prodrug therapy for prostate cancer in the near future.

     

/

返回文章
返回